2022 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF):
| Silent period | 11 January 2022 |
| Annual report 2021 | 8 February 2022 |
| Annual General Meeting to be held at ALK Bøge Allé 1 2970 Hørsholm, Denmark Written requests to have specific business |
16 March 2022 4.00 p.m. |
| Silent period | 14 April 2022 |
| Three-month interim report (Q1) 2022 | 12 May 2022 |
| Silent period | 14 July 2022 |
| Six-month interim report (Q2) 2022 | 11 August 2022 |
| Silent period | 13 October 2022 |
| Nine-month interim report (Q3) 2022 | 10 November 2022 |
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…
AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…
Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…
Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…